Sustained Release Oral Formulation for Treatment of Parkinson's Disease

Status Not yet recruiting

Clinical Trial Summary

Achieving sustained blood levels of carbidopa/levodopa has been a challenge in the treatment of PD and although levodopa remains the most commonly used drug, motor fluctuations remain a major disability especially in advanced Parkinson's disease. The aim of this study is to determine the efficacy of a novel oral carbidopa-levodopa formulation in achieving a sustained blood level of levodopa and carbidopa in PD.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05471609
Study type	Interventional
Source	University of Minnesota
Contact	Diane Hutter, RN
Phone	612-625-2350
Email	hutte019@umn.edu
Status	Not yet recruiting
Phase	Early Phase 1
Start date	March 15, 2024
Completion date	March 16, 2025

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05103618` - Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA	Phase 2
Completed	`NCT03700684` - Voice Treatment for Parkinson's Disease	N/A
Completed	`NCT04202757` - Intravenous Plasma Treatment for Parkinson's Disease	Early Phase 1
Completed	`NCT05027620` - Feasibility of Motor-cognitive Home Training for Parkinson's Disease Using eHealth Technology	N/A
Completed	`NCT03652363` - GDNF in ideopathicParkinsons Disease	Phase 2
Recruiting	`NCT02960464` - tDCS for Treatment of Depression in Parkinson's Disease	N/A
Completed	`NCT05699161` - Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson	Phase 1/Phase 2
Completed	`NCT03944785` - Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)
Completed	`NCT01227265` - Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)	Phase 3
Terminated	`NCT01215227` - An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)	Phase 3
Withdrawn	`NCT05832775` - Study to Assess the Safety of MRx0029 or MRx0005 Compared to Placebo, in People With Parkinson's	Phase 1
Active, not recruiting	`NCT02780895` - Parkinsonian Brain Repair Using Human Stem Cells	Phase 1
Recruiting	`NCT01860794` - Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease	Phase 1/Phase 2
Completed	`NCT02373072` - A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease	Phase 1
Terminated	`NCT02393027` - Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999	Early Phase 1
Completed	`NCT02445651` - Physiological Effects of Nutritional Support in Patients With Parkinson's Disease	N/A
Completed	`NCT00437125` - Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease	Phase 4
Completed	`NCT02723396` - Sleep, Awake & Move - Part I
Completed	`NCT00599339` - Transdermal Rotigotine User Surveillance Study
Completed	`NCT00160576` - Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias	Phase 2